Danske Bank A S increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 59.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 311,007 shares of the medical device company’s stock after buying an additional 115,958 shares during the quarter. Danske Bank A S’s holdings in DexCom were worth $26,837,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in DexCom in the 2nd quarter worth $173,237,000. Deutsche Bank AG acquired a new stake in DexCom during the 2nd quarter worth about $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after acquiring an additional 1,515,702 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in DexCom during the 2nd quarter valued at about $89,940,000. Finally, Arrowstreet Capital Limited Partnership grew its stake in DexCom by 100.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock valued at $159,832,000 after purchasing an additional 1,275,142 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the sale, the executive vice president directly owned 126,043 shares in the company, valued at approximately $11,138,419.91. This trade represents a 1.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 22,822 shares of company stock worth $1,920,193. Corporate insiders own 0.28% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on DXCM
DexCom Trading Down 2.1%
Shares of DexCom stock opened at $81.61 on Tuesday. The stock has a market cap of $30.44 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 1.34 and a beta of 1.45. The firm has a fifty day moving average price of $84.17 and a 200 day moving average price of $75.25. DexCom, Inc. has a 1 year low of $56.72 and a 1 year high of $92.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.61 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.68 earnings per share for the current year.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Recommended Stories
- Five stocks we like better than DexCom
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
